The content on this site is intended for healthcare professionals only
Dr Fox speaks at the 'measuring success in indolent disease' session during BSH 2017 in Brighton, UK.
Fox discusses what to do when standard treatment fails.
The content available here was filmed at a Roche Products Limited promotional symposium and contains discussion of Roche medicines.
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
KRdc as induction therapy shows improved OS for NDMM patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
Multiple myeloma in a resource constrained setting
